Summery: Nivolumab has revolutionized therapy of advanced cancers. Currently Nivolumab is approved for several cancers including advanced non-small-cell lung cancer (NSCLC), Malignant Pleural Mesothelioma, metastatic renal cell carcinoma (RCC), head-and-neck squamous cell carcinoma (HNSCC) Hodgkin's lymphoma, advanced Hepatocellular Carcinoma, advanced Esophageal and Gastric Cancer. Most dose finding trials did not find relevant dose for Nivolumab. Hence at times a lower dose that what should be given is used in treatments. However, it is limited in scope due to variation in patient characteristics and dose of nivolumab employed. Given the prevalent cost constraints in low- and middle-income countries, we are conducting this study in patients with advanced cancers to evaluate the effectiveness and the safety low dose nivolumab.